

HR 3379

PRICED Act

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Jun 20, 2019

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Jun 21, 2019)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/3379>

Sponsor

Name: Rep. Schakowsky, Janice D. [D-IL-9]

Party: Democratic • **State:** IL • **Chamber:** House

Cosponsors (22 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Cicilline, David N. [D-RI-1]	D · RI		Jun 20, 2019
Rep. Craig, Angie [D-MN-2]	D · MN		Jun 20, 2019
Rep. DeLauro, Rosa L. [D-CT-3]	D · CT		Jun 20, 2019
Rep. Doggett, Lloyd [D-TX-35]	D · TX		Jun 20, 2019
Rep. Garcia, Jesus G. "Chuy" [D-IL-4]	D · IL		Jun 20, 2019
Rep. Jayapal, Pramila [D-WA-7]	D · WA		Jun 20, 2019
Rep. Kaptur, Marcy [D-OH-9]	D · OH		Jun 20, 2019
Rep. Khanna, Ro [D-CA-17]	D · CA		Jun 20, 2019
Rep. Krishnamoorthi, Raja [D-IL-8]	D · IL		Jun 20, 2019
Rep. Levin, Andy [D-MI-9]	D · MI		Jun 20, 2019
Rep. Morelle, Joseph D. [D-NY-25]	D · NY		Jun 20, 2019
Rep. Pocan, Mark [D-WI-2]	D · WI		Jun 20, 2019
Rep. Rush, Bobby L. [D-IL-1]	D · IL		Jun 20, 2019
Rep. Tlaib, Rashida [D-MI-13]	D · MI		Jun 20, 2019
Rep. Welch, Peter [D-VT-At Large]	D · VT		Jun 20, 2019
Rep. Westerman, Bruce [R-AR-4]	R · AR		Jun 20, 2019
Rep. Ocasio-Cortez, Alexandria [D-NY-14]	D · NY		Jun 25, 2019
Rep. Chu, Judy [D-CA-27]	D · CA		Jul 12, 2019
Rep. Lee, Barbara [D-CA-13]	D · CA		Jul 12, 2019
Del. Norton, Eleanor Holmes [D-DC-At Large]	D · DC		Oct 11, 2019
Rep. Meng, Grace [D-NY-6]	D · NY		Oct 11, 2019
Rep. Raskin, Jamie [D-MD-8]	D · MD		Oct 11, 2019

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Jun 21, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
116 S 4796	Related bill	Oct 5, 2020: Read twice and referred to the Committee on Finance.
116 HR 8527	Related bill	Oct 2, 2020: Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, Education and Labor, the Judiciary, Oversight and Reform, House Administration, Rules, the Budget, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Summary (as of Jun 20, 2019)

Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act

This bill allows biosimilars to be marketed five years after the reference brand-name biological product is licensed. Currently, brand-name biological products are provided a 12-year marketing-exclusivity period.

This shortened marketing-exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.

Actions Timeline

- **Jun 21, 2019:** Referred to the Subcommittee on Health.
- **Jun 20, 2019:** Introduced in House
- **Jun 20, 2019:** Referred to the House Committee on Energy and Commerce.